MannKind sends insulin to FDA

Share this article:

Two months after releasing Phase III data over its inhaled insulin, MannKind announced Monday it has resubmitted its FDA application for Afrezza.

The FDA rejected the drug three years ago when the manufacturer submitted data that predated an inhaler change.

Clearing the FDA would put Afrezza on previously trod ground. Pfizer abandoned its inhaled insulin Exubera following poor sales. Novo and Lilly have also left inhaled insulin efforts in the dust.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.